The advance may help clinicians protect patients’ heart health and prevent strokes.
- Investigators have developed and tested a targeted contrast agent that can detect blood clots in the hearts of patients with atrial fibrillation, or an irregular heartbeat.
- The strategy could be used to find clots in other parts of the body as well, such as in vessels that, when blocked, can lead to stroke.
David Sosnovik, MD, FACC
The idea behind the technology is that the agent will find and bind to blood clots anywhere in the body—not just in the heart—and make the clots detectable like a bright star in the night sky.
Director, Program in Cardiovascular Imaging, Martinos Center for Biomedical Imaging, Massachusetts General Hospital
BOSTON – Atrial fibrillation—an irregular and often rapid heart rate—is a common condition that can cause clots to form in the heart that may then dislodge and flow to the brain, potentially leading to a stroke. The standard way to detect these clots requires patients to be sedated and to have a fairly large tube inserted down the throat and esophagus for a transesophageal ultrasound. Investigators at Massachusetts General Hospital (MGH) have now developed and tested a targeted contrast agent to detect and image these clots noninvasively. They verified the potential of this strategy in a study published in JACC: Cardiovascular Imaging.
The agent has a strong affinity for fibrin, a component of blood clots, and is detected with a radioactive copper tag. “The idea behind the technology is that the agent will find and bind to blood clots anywhere in the body—not just in the heart—and make the clots detectable like a bright star in the night sky,” says senior author David Sosnovik, MD, FACC, director of the Program in Cardiovascular Imaging within MGH’s Martinos Center for Biomedical Imaging and an associate professor of Medicine at Harvard Medical School. “In some ways this is analogous to doing a smart search with a search engine such as Google, where the search terms one uses guide the search. We inject the agent into a small peripheral vein and it circulates throughout the human body on its search for clots.” If it doesn’t find any clots, then it’s rapidly excreted from the body; however, if it finds a clot and binds to it, clinicians can detect it with an imaging technique known as positron emission tomography.
Sosnovik and his colleagues first examined how the agent reacts (specifically, its metabolism and pharmacokinetics) in eight healthy volunteers. After injection, the agent was initially stable within the body and then was cleared from tissues within several hours, suggesting that it was safe. Next, the team administered the agent to patients with atrial fibrillation, some with clots in the heart and some without. Imaging tests of the heart revealed bright signals within the clots that were not seen in patients without clots.
“Obviously much more work and many more studies will need to be done before this changes routine clinical practice, but this first-in-human study is an important step,” says Sosnovik. “Importantly, this smart or molecularly targeted agent can be used to detect clots anywhere in the body.”
Sosnovik stressed that the multidisciplinary nature of this project was critical to its success, with vital roles played by diverse scientists, including Peter Caravan, PhD, who invented and developed the study’s agent and is the co-director of MGH’s Institute for Innovation in Imaging. “This probe was invented and optimized in my laboratory by a dedicated team of chemists and biologists through the support of the National Heart Lung and Blood Institute of the National Institutes of Health,” says Caravan. “It is extremely gratifying to see these years of effort come to fruition with a fibrin-specific PET probe with the potential to make a real impact on human health.”
Others playing a major role in the study included David Izquierdo-Garcia, PhD, an assistant in Biomedical Engineering at MGH, and Ciprian Catana, MD, PhD, director of Integrated MR-PET Imaging at MGH’s Martinos Center for Biomedical Imaging. Izquierdo-Garcia, the lead author on the paper, and Catana both stressed the innovative nature of the imaging platform used in the study. “Not only did we use a novel molecular imaging probe in humans for the first time, but also, this is one of the first studies to fully explore the synergies and advantages of integrated PET-MRI scanners,” says Izquierdo-Garcia.
“It is a privilege to work at the Martinos Center for Biomedical Imaging and be part of multidisciplinary teams that collaborate to develop and apply cutting-edge imaging technologies,” adds Catana. “We were the first site in the U.S. to install a fully integrated PET-MRI scanner and have played a major role in the advancement and clinical translation of this technology.”
Additional co-authors include Pauline Désogère, PhD, Anne L. Philip, MPH, Choukri Mekkaoui, PhD, Rory B. Weiner, MD, Onofrio A. Catalano, MD, Yin-Ching Iris Chen, PhD, Doreen DeFaria Yeh, MD, and Moussa Mansour, MD.
Funding for the study was provided by the National Institutes of Health.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2021, Mass General was named #5 in the U.S. News & World Report list of "America’s Best Hospitals."
- Press Release
- May | 25 | 2021
The use of accelerometers enables researchers to provide the most objective evidence to date of the link between physical activity and atrial fibrillation.